Follow-on roundup: Sangamo, Tricida, DBV

Sangamo and Tricida each priced follow-ons soon after their share prices spiked on recent clinical readouts. DBV also raised a follow-on ahead of a planned BLA resubmission.

Sangamo Therapeutics Inc. (NASDAQ:SGMO) raised $126.5 million on Thursday

Read the full 351 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE